SEC Tracker
Get the app

SI-BONE SIBN

SI-BONE FY 2024: revenue $167.2M, up 20%; diluted EPS −$0.75

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers SI-BONE reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$167.2M+20% from $138.9M in FY 202310-K income statement, on EDGAR
  2. Net income−$30.9MAgainst −$43.3M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS−$0.75Against −$1.13 in FY 202310-K income statement, on EDGAR
  4. Cash and cash equivalents$34.9M+5% from $33.3M in FY 202310-K balance sheet, on EDGAR
  5. Cash from operations−$12.4MAgainst −$18.7M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when SI-BONE files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Biolife Solutions BLFS public float $845M, Jun 30, 2025
  2. Embecta EMBC public float $732M, Mar 31, 2025, over 18 months old
  3. Mimedx Group MDXG public float $719M, Jun 30, 2025
  4. Heartflow HTFL
  5. Integra Lifesciences Holdings IART public float $925M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.